Abstract
For several years, there has been a significant increase in the number of patients diagnosed with cardiac amyloidosis. However, there are still difficulties associated with the diagnosis, identifying its type and further treatment of the disease. The diversity of the clinical symptoms, the absence of pathognomonic symptoms make it difficult to diagnose, which leads to the progression of the disease. Heart involvement is the main cause of morbidity and mortality in systemic amyloidosis, regardless of the underlying pathogenesis of amyloid production, and in most cases amyloid cardiomyopathy is clinically manifested by rapidly progressive symptoms of heart failure. The article presents a clinical case of a patient with a hereditary type of systemic transthyretin amyloidosis with the involvement of heart, kidneys, liver, nervous system, and the identified mutation in the TTR gene (p.Y89F) has not been previously described in the Russian Federation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
